阿托西班对先兆早产的疗效及对新生儿结局的影响分析

Analysis of the efficacy of atoxiban on threatened preterm birth and its impact on neonatal outcomes

目的探讨阿托西班对先兆早产的疗效及对新生儿结局的影响。方法选取2016年5月至2019年7月南京医科大学附属常州妇幼保健院收治的40例先兆早产住院患者作为研究对象,采用随机数字表法分为观察组与对照组,每组20例。对照组给予常规盐酸利托君治疗,观察组给予新型药物阿托西班治疗。比较两组临床疗效相关指标、新生儿结局、治疗48 h及7 d的有效率、不良反应发生情况。结果观察组宫缩有效抑制时间短于对照组,妊娠延长时间长于对照组,差异有统计学意义(P<0.05)。观察组不良新生儿结局发生率低于对照组,治疗48 h的有效率高于对照组,差异有统计学意义(P<0.05);两组治疗7 d时的有效率比较差异无统计学意义。观察组不良反应发生率为5.00%,低于对照组的40.00%,差异有统计学意义(P<0.05)。结论阿托西班治疗先兆早产的疗效显著,可提高治疗48 h时的有效率,有效降低不良新生儿结局发生率及用药不良反应发生风险,值得临床推广应用。

Objective To explore the efficacy of atoxiban on threatened preterm birth and its impact on neonatal outcomes.Methods 40 hospitalized patients with threatened preterm birth admitted to Changzhou Maternal and Child Health Hospital Affiliated to Nanjing Medical University from May 2016 to July 2019 were selected as the study subjects,they were divided into the observation group and the control group according to the random number table method,with 20 cases in each group.The control group received conventional treatment with rituximab hydrochloride,while the observation group received treatment with the new drug atoxiban,the clinical efficacy related indicators,neonatal outcomes,48 h and 7 d effective rates,and incidence of adverse reactions were compared between the two groups.Results The effective inhibition time of uterine contractions in the observation group was shorter than that in the control group,and the pregnancy extension time was longer than that in the control group,the differences were statistically significant(P<0.05).The incidence of adverse neonatal outcomes in the observation group was lower than that in the control group,and the effective rate of treatment for 48 h was higher than that in the control group,the differences were statistically significant(P<0.05);there was no statistically significant difference in the effective rate after 7 d of treatment between the two groups.The incidence of adverse reactions in the observation group was 5.00%,which was lower than 40.00%in the control group,and the difference was statistically significant(P<0.05).Conclusion Atoxiban has significant clinical efficacy in the treatment of threatened preterm birth,can improve the effective rate at 48 h of treatment,effectively reduce the incidence of adverse neonatal outcomes and the risk of adverse drug reactions,and is worthy of clinical promotion and application.